Viatris, Inc. is a leading pharmaceutical company in the United States of America. With a medium risk rating score of 25.3, Viatris specializes in generic and specialty drugs, servicing over 165 countries worldwide. The company was formed in November 2020 through a merger between Upjohn and Mylan. Viatris focuses on generics, biosimilars, and legacy products such as Lipitor and Viagra. With a diverse portfolio covering more than 10 major therapeutic areas, Viatris is committed to innovation in dermatology, ophthalmology, and gastroenterology.